A detailed history of Alliancebernstein L.P. transactions in Biogen Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 281,289 shares of BIIB stock, worth $48.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
281,289
Previous 201,891 39.33%
Holding current value
$48.9 Million
Previous $43.5 Million 49.79%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$190.52 - $236.72 $15.1 Million - $18.8 Million
79,398 Added 39.33%
281,289 $65.2 Million
Q1 2024

May 14, 2024

SELL
$212.02 - $267.71 $5.92 Million - $7.47 Million
-27,922 Reduced 12.15%
201,891 $43.5 Million
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $4.83 Million - $5.81 Million
-21,691 Reduced 8.62%
229,813 $59.5 Million
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $2.81 Million - $3.17 Million
11,105 Added 4.62%
251,504 $64.6 Million
Q2 2023

Aug 15, 2023

SELL
$275.25 - $318.06 $14.6 Million - $16.9 Million
-53,124 Reduced 18.1%
240,399 $68.5 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $13 Million - $14.8 Million
50,545 Added 20.8%
293,523 $81.6 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $2.68 Million - $3.25 Million
10,599 Added 4.56%
242,978 $67.3 Million
Q3 2022

Nov 15, 2022

BUY
$194.69 - $268.46 $350,636 - $483,496
1,801 Added 0.78%
232,379 $62 Million
Q2 2022

Aug 15, 2022

BUY
$187.54 - $223.02 $6.77 Million - $8.05 Million
36,088 Added 18.56%
230,578 $47 Million
Q1 2022

May 13, 2022

BUY
$193.77 - $244.14 $151,528 - $190,917
782 Added 0.4%
194,490 $41 Million
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $9.84 Million - $12.6 Million
-43,928 Reduced 18.49%
193,708 $46.5 Million
Q3 2021

Nov 10, 2021

BUY
$282.99 - $369.05 $2.06 Million - $2.69 Million
7,277 Added 3.16%
237,636 $67.2 Million
Q2 2021

Jul 30, 2021

SELL
$259.0 - $414.71 $7 Million - $11.2 Million
-27,014 Reduced 10.5%
230,359 $79.8 Million
Q1 2021

May 06, 2021

SELL
$242.95 - $284.63 $4.76 Million - $5.58 Million
-19,602 Reduced 7.08%
257,373 $72 Million
Q4 2020

Feb 08, 2021

BUY
$236.26 - $355.63 $1.41 Million - $2.12 Million
5,955 Added 2.2%
276,975 $67.8 Million
Q3 2020

Nov 12, 2020

SELL
$264.77 - $305.71 $2.83 Million - $3.27 Million
-10,691 Reduced 3.8%
271,020 $76.9 Million
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $9.07 Million - $12 Million
-35,082 Reduced 11.07%
281,711 $75.4 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $30.6 Million - $38.8 Million
-113,661 Reduced 26.4%
316,793 $100 Million
Q4 2019

Feb 18, 2020

SELL
$220.06 - $304.07 $234 Million - $324 Million
-1,064,632 Reduced 71.21%
430,454 $128 Million
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $51.2 Million - $57.4 Million
-235,507 Reduced 13.61%
1,495,086 $348 Million
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $170 Million - $187 Million
-773,943 Reduced 30.9%
1,730,593 $405 Million
Q1 2019

May 14, 2019

SELL
$216.71 - $338.96 $70.8 Million - $111 Million
-326,692 Reduced 11.54%
2,504,536 $592 Million
Q4 2018

Feb 13, 2019

SELL
$278.5 - $352.75 $80.7 Million - $102 Million
-289,916 Reduced 9.29%
2,831,228 $852 Million
Q3 2018

Nov 08, 2018

SELL
$293.51 - $383.83 $208 Million - $273 Million
-710,281 Reduced 18.54%
3,121,144 $1.1 Billion
Q2 2018

Aug 13, 2018

SELL
$257.52 - $306.91 $49.8 Million - $59.3 Million
-193,345 Reduced 4.8%
3,831,425 $1.11 Billion
Q1 2018

May 14, 2018

BUY
$260.13 - $367.91 $159 Million - $224 Million
610,098 Added 17.87%
4,024,770 $1.1 Billion
Q4 2017

Feb 13, 2018

BUY
$307.64 - $344.58 $224 Million - $251 Million
727,007 Added 27.05%
3,414,672 $1.09 Billion
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $756 Million - $886 Million
2,687,665
2,687,665 $842 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.